IMR Press / EJGO / Volume 42 / Issue 5 / DOI: 10.31083/j.ejgo4205148
Open Access Review
Treatment strategies for ovarian cancer focusing on prostaglandins
Show Less
1 Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, 036-8562 Hirosaki, Japan
Eur. J. Gynaecol. Oncol. 2021, 42(5), 996–1000;
Submitted: 23 June 2021 | Revised: 26 July 2021 | Accepted: 12 August 2021 | Published: 15 October 2021
(This article belongs to the Special Issue Immunotherapy for Gynecological Oncology)

This work aims to researching the potential of anti-inflammatory therapy as an adjuvant in the antiblastic treatment for ovarian cancers. Drugs commonly used for dyslipidemia and diabetes mellitus and anti-inflammatory drugs have tumor-suppressing effects via anti-angiogenic and apoptosis-inducing actions. Proinflammatory prostaglandins (PGs) promote angiogenesis and suppress apoptosis. A therapeutic agent for dyslipidemia, Clofibric acid increases carbonyl reductase 1 (CBR1), which inactivates PGs in the tumor, and exerts a tumor shrinkage effect. Oral hypoglycemic agents, ciglitazone and pioglitazone reduce PG synthase and cyclooxygenase (COX) 2 in tumors and shrink them. A selective COX-2 inhibitor, Meloxicam directly inhibits PG production and shrinks tumors. These facts remind us of the importance of drug repositioning. Considering that the safety has been established including side effects, these drugs have the potential to be used not only to treat ovarian cancer but also human solid cancers in general as a combination adjuvant drug with other anticancer agents or to be applied to tumor dormancy therapy with different properties from anticancer agents.

Ovarian cancer
Clofibric acid
Carbonyl reductase
Oral hypoglycemic agents
Fig. 1.
Back to top